Cognitive Behavioral Therapy for Chronic Insomnia
A Systematic Review and Meta-analysis

James M. Trauer, MBBS; Mary Y. Qian, MBBS; Joseph S. Doyle, PhD; Shantha M.W. Rajaratnam, PhD; and David Cunnington, MBBS

Background: Because psychological approaches are likely to produce sustained benefits without the risk for tolerance or adverse effects associated with pharmacologic approaches, cognitive behavioral therapy for insomnia (CBT-i) is now commonly recommended as first-line treatment for chronic insomnia.

Purpose: To determine the efficacy of CBT-i on diary measures of overnight sleep in adults with chronic insomnia.

Data Sources: Searches of MEDLINE, EMBASE, PsycINFO, CINAHL, the Cochrane Library, and PubMed Clinical Queries from inception to 31 March 2015, supplemented with manual screening.

Study Selection: Randomized, controlled trials assessing the efficacy of face-to-face, multimodal CBT-i compared with inactive comparators on overnight sleep in adults with chronic insomnia. Studies of insomnia comorbid with medical, sleep, or psychiatric disorders were excluded.

Data Extraction: Study characteristics, quality, and data were assessed independently by 2 reviewers. Main outcome measures were sleep onset latency (SOL), wake after sleep onset (WASO), total sleep time (TST), and sleep efficiency (SE%).

Data Synthesis: Among 292 citations and 91 full-text articles reviewed, 20 studies (1162 participants [64% female; mean age, 56 years]) were included. Approaches to CBT-i incorporated at least 3 of the following: cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation. At the posttreatment time point, SOL improved by 19.03 (95% CI, 14.12 to 23.93) minutes, WASO improved by 26.00 (CI, 15.48 to 36.52) minutes, TST improved by 7.61 (CI, −0.51 to 15.74) minutes, and SE% improved by 9.91% (CI, 8.09% to 11.73%). Changes seemed to be sustained at later time points. No adverse outcomes were reported.

Limitation: Narrow inclusion criteria limited applicability to patients with comorbid insomnia and other sleep problems, and accuracy of estimates at later time points was less clear.

Conclusion: CBT-i is an effective treatment for adults with chronic insomnia, with clinically meaningful effect sizes.

Primary Funding Source: None. (PROSPERO registration number: CRD42012002863)

Insomnia is a prevalent condition, with 5% to 15% of adults meeting formal diagnostic criteria for chronic insomnia (1–5) (now termed insomnia disorder [6]) and one third reporting dissatisfaction with sleep. Insomnia is associated with both medical and psychiatric comorbidity, being linked to anxiety; depression (7); chronic health problems, such as hypertension (8, 9) and type 2 diabetes (10); health care use; non–motor vehicle accidents; pain (11); and use of medication and alcohol (12–15). Symptoms of insomnia have functional consequences even in the absence of a formal diagnosis (16), with the high economic burden of the condition largely mediated through the productivity cost of work absenteeism (17).

Hypnotics, such as benzodiazepines and related drugs, are the most commonly used treatment for insomnia, with around 6% to 10% of U.S. adults using hypnotics in 2010 (18) and 27 daily doses of such drugs being taken per 1000 U.S. persons (19). In Australia, around 90% of primary care encounters for insomnia result in hypnotic prescription (20). Furthermore, despite a lack of evidence, use of second-generation antipsychotics (such as quetiapine) is also increasing, possibly due to patient and physician dissatisfaction with available treatments and a perceived lack of alternatives (21, 22). In this context, considering nonpharmacologic treatment options for insomnia disorder is important.

Cognitive behavioral therapy for insomnia (CBT-i) is an effective nonpharmacologic treatment that improves sleep outcomes with minimal adverse effects (23) and is preferred by patients to drug therapy (24). The approach to CBT-i has been refined in recent years, and it is now most commonly studied as a combined cognitive and behavioral treatment incorporating some or all of 5 components. The components are described in **Table 1**, and although the precise efficacy of each has not been determined, the package of care is more effective than separate delivery of the cognitive or behavioral components (25). Although previous meta-analyses have been performed (26–29), no recent meta-analysis has assessed the efficacy of this now-established package of care. We present a meta-analysis of the efficacy of CBT-i on sleep diary outcomes, compared with control, for the treatment of adults with chronic insomnia.

Table 1. Components of CBT-i

Component	Description
Cognitive therapy	Aims to identify, challenge, and replace dysfunctional beliefs and attitudes about sleep and insomnia. Such misconceptions may include unrealistic expectations of sleep, fear of missing out on sleep, and overestimation of the consequences of poor sleep.
Stimulus control	Behavioral instructions aimed at strengthening the association between bed and sleep and preventing conditioning of the patient to associate bed with other stimulating activities. Such instructions include avoiding nonsleep activities in the bedroom; going to bed only when sleepy; and leaving the bedroom when unable to sleep for 15–20 min, returning to bed only when sleepy.
Sleep restriction	Behavioral instructions to limit time in bed to match perceived sleep duration in order to increase sleep drive and further reduce time awake in bed. Time allowed in bed is initially restricted to the average time perceived as sleep per night and then adjusted to ensure sleep efficiency remains >85%.
Sleep hygiene	General recommendations relating to environmental factors, physiologic factors, behavior, and habits that promote sound sleep. Specific instructions include advice on control of the bedroom environment, including avoiding visual access to a clock; regular sleep scheduling and avoiding long daytime naps; and limiting alcohol, caffeine, and nicotine intake, especially before bed.
Relaxation	Any relaxation technique that the patient finds effective can be used to limit cognitive arousal and reduce muscular tension to facilitate sleep. Specific techniques that may be used include meditation, mindfulness, progressive muscle relaxation, guided imagery, and breathing techniques.

CBT-i = cognitive behavioral therapy for insomnia.

METHODS

We performed a systematic review and meta-analysis in accordance with the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines, using methods from the Cochrane Handbook for Systematic Reviews of Interventions. The predetermined methods were registered online with PROSPERO (CRD42012002863) (30), with full methods presented in section 1 of the **Supplement** (available at www.annals.org).

Data Sources and Searches

We searched MEDLINE, EMBASE, PsycINFO, CINAHL, the Cochrane Library, and PubMed Clinical Queries from inception to 31 March 2015 with the terms "sleeplessness," "chronic insomnia," "insomniac," "insomnia," "insomni*," "sleep initiation and maintenance disorders," "cognitive behavioural therapy," "cognitive behavioral therapy," "cognitive behavioural therapies," "cognitive behavioral therapies," "sleep hygiene," "stimulus control," "relaxation," "relaxation techniques," "behavior modification," "behavior therapy," "cognitive therapy," "imagery," and "psychotherapy" in any language. We also reviewed the reference lists of 4 review articles on the topic (26–28, 31) and briefly screened references by using the same search strategy without limitation to randomized, controlled trials.

Study Selection

Eligible studies were randomized, controlled trials involving CBT-i in adults (aged ≥18 years) with chronic insomnia. We defined CBT-i as multimodal therapy delivered in person on at least 2 occasions and incorporating at least 2 of the 5 most widely accepted components of CBT-i: cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation therapy. For the primary analysis, acceptable control groups included sham therapy, waiting list, no treatment, sleep hygiene, or information provision.

Studies were excluded if medical, sleep, or psychiatric comorbid conditions were listed as inclusion criteria, but they were not excluded on the basis of the frequency of comorbid conditions in included patients. We adopted this approach because excluding all studies that allowed patients with comorbid conditions would have markedly depleted the number of included studies, and because patients with chronic insomnia seen in clinical practice are likely to have a range of noninteracting comorbid conditions. Moreover, because only a subgroup of included studies reported the proportion of patients with comorbid conditions, we wished to avoid penalizing studies that reported in greater detail.

Data Extraction and Quality Assessment

Two authors independently confirmed the eligibility of studies, with all discrepancies resolved by consensus. One of these 2 authors extracted data, which were verified by a third author. We contacted the corresponding author of all included studies published after 1 January 2000 to request clarification of data and methods. Study quality assessments were performed independently by the 2 authors who extracted and verified data using the Cochrane Collaboration tool for assessing risk of bias (32).

Data Synthesis and Analysis

Our main outcome measures of interest were sleep diary measures of sleep onset latency (SOL), wake after sleep onset (WASO), total sleep time (TST), and sleep efficiency (SE%) (**Table 2**). These end points were assessed at 3 time points that we defined for the purpose of this analysis: immediately after treatment, early follow-up (4 weeks to <6 months after completion of the intervention), and late follow-up (6 to 12 months after completion of the intervention). Because studies most frequently reported results as the mean and SD at a point in time rather than the SD of the mean change over time, the SD of the change over time was imputed in most cases. All analyses used random-effects models, with heterogeneity assessed using the I^2 statistic and publication bias assessed with funnel plots and the Egger test (33, 34).

Table 2. Glossary

Outcome Measure	Definition	Abbreviation	Unit
Sleep onset latency	Average time to enter sleep after lights out, over the diary period	SOL	Minutes
Wake after sleep onset	Average time spent awake during the night after first entering sleep, over the diary period	WASO	Minutes
Total sleep time	Average total nighttime sleep, over the diary period	TST	Minutes
Sleep efficiency	Total sleep time divided by average time spent in bed, over the diary period	SE%	Percentage

Six sensitivity analyses were performed that were limited to studies with particular intervention characteristics. First, we limited the analysis to studies incorporating sleep restriction because this may be among the most effective components of CBT-i (35). Second, because the optimal dosage of CBT-i is unknown but may be 4 sessions (36), we limited the analysis to studies involving at least 4 in-person contacts. Third, to consider the incremental effect of CBT-i incorporating a greater number of components, we limited the analysis to studies involving at least 4 components. Fourth, we limited the analysis to studies using a comparator group other than sleep hygiene because this may or may not be an effective stand-alone treatment (31). Fifth, we restricted the analysis to studies delivering treatment on an individual basis only, rather than in a group setting. Finally, to determine whether a tendency existed for studies with significant results to follow patients longer, we restricted the posttreatment analysis to studies with follow-up time points. In addition, we performed 3 sensitivity analyses in which we varied the correlation coefficients used to impute SDs.

All statistical tests were 2-tailed, with P values less than 0.05 considered statistically significant. Statistical analyses were performed using Stata, version 13.0 (StataCorp), and R, version 3.1.3 (R Foundation for Statistical Computing).

Role of the Funding Source

This study received no funding.

RESULTS

Our formal search strategy identified 292 references for review of the title and abstract. Of these, the full text was obtained and reviewed for 91 articles that were considered potentially appropriate for inclusion, and 20 studies met all inclusion criteria (although only 19 contributed data to the pooled estimates presented). The study flow diagram with reasons for exclusion is presented in **Figure 1**.

Study Characteristics

Table 3 shows descriptive data for the 20 included studies, which involved a total of 1162 patients (range, 20 to 201 patients), with values presented for only the groups that contributed data to this meta-analysis when possible. Most study populations were of late or middle age (mean age, 55.6 years), and 9 studies incorporated age restrictions as exclusion criteria. Sex was predominantly female (64.3%), and most studies were performed in developed countries (n = 19). Of the studies excluded on the basis of the population studied, 5 enrolled hypnotic-dependent patients, 1 enrolled obese

persons, 3 enrolled patients with any comorbid condition, 1 enrolled patients with moderate to severe hot flashes, and 3 did not require a formal diagnosis of insomnia. Most studies referenced accepted definitions for insomnia (n = 17), most often an edition of the *Diagnostic and Statistical Manual of Mental Disorders* (n = 13), the International Classification of Sleep Disorders (n = 7), or both (**Table 3**). Nineteen studies excluded patients on the basis of presence of comorbid conditions, with all of these excluding patients with psychiatric or sleep-related comorbid conditions, 17 excluding those with medical comorbid conditions, 17 excluding those with medication or drug use, 4 excluding pregnant women, and 3 excluding shift workers. However, approaches differed in whether any comorbid condition was sufficient for exclusion or whether only patients with severe, unstable, or treatment-requiring conditions were excluded. Fourteen studies screened all patients with polysomnography at baseline to detect unrecognized sleep disorders.

All studies investigated multimodal CBT-i with at least 3 components, even though only 2 were required for inclusion. Seven included studies delivered CBT-i in a group setting, and the remainder delivered it individually, some with adjunctive aids, such as telephone support, audiocassettes, or written material.

Comparator control groups consisted of a waiting list or usual treatment (n = 7), sleep hygiene instructions or education (n = 6), a sham behavioral intervention (n = 3), or placebo tablets (in studies in which a third group received pharmacotherapy [n = 4]).

Study Quality

Only 1 study was universally assessed as having low risk of bias across all domains (**Table 4**). Sequence generation generally followed accepted methods, although it was unreported in some studies, and allocation concealment was usually not reported. Many studies did not report blinding techniques in detail, possibly because the researchers assumed that blinding was not feasible due to the nature of the intervention, with no study describing complete blinding of all participants and personnel. Studies listed as low-risk on this domain usually described providing patients with general information that the trial was considering different behavioral treatments for insomnia. Risk of bias from incomplete outcome data is presented with regard only to those participant groups contributing data to this meta-analysis and only to the posttreatment time point. Risk was considered high on this domain if either a large proportion (>20%) of participants contributing data were lost to follow-up or if a significant proportion (>10%) of participants were lost without use of an ap-

Figure 1. Summary of evidence search and selection.

CBT-i = cognitive behavioral therapy for insomnia; RCT = randomized, controlled trial.
* Restricted to references not returned on MEDLINE search.

propriate statistical method to account for dropouts (for example, intention-to-treat analysis with last observation carried forward or imputation for missing data). Under these criteria, most included studies were assessed as low-risk on this domain, and no tendency was observed toward high risk of bias among studies not contributing follow-up data. Bias from selective outcome reporting was assessed as low if at least 3 standard sleep diary measures were reported in numerical form, and most studies consistently reported these outcomes.

Main Efficacy Meta-analysis

Results for the main outcomes of sleep diary measures of SOL, WASO, TST, and SE% are presented in **Figures 2** to **5**. Marked and statistically significant improvements in SOL (19.03 minutes [95% CI, 14.12 to 23.93 minutes; I^2 = 41.9%]), WASO (26.00 minutes [CI, 15.48 to 36.52 minutes; I^2 = 47.2%]), and SE% (9.91% [CI, 8.09% to 11.73%; I^2 = 47.1%]) were observed at the

posttreatment time point. Although the magnitude of the change seemed to be similar at both the early and late time points for all 3 of these outcomes, statistical significance was generally borderline because fewer studies were available for meta-analysis at these time points. Total sleep time seemed to improve marginally at the posttreatment time point (7.61 minutes [CI, −0.51 to 15.74 minutes; I^2 = 3.1%]), and although this improvement seemed to augment at later time points, statistical significance was not achieved at any time point.

Secondary End Points

To compare the effect of CBT-i on sleep diary outcomes, with its effects on the same outcomes measured by different methods, measures of sleep time using polysomnography and actigraphy were considered at the posttreatment time point. The full results of these meta-analyses are presented in section 2 of the **Supplement** and are summarized in the **Appendix Table** (avail-

able at www.annals.org). For polysomnography, for which up to 5 studies were available for meta-analysis, estimates for effect sizes were similar to those seen for sleep diary measures of the same estimates. However, for actigraphy, for which up to 3 studies were analyzed, the effect size estimates were notably lower than for both sleep diary measures and polysomnography.

Although most studies reported questionnaire-based results for subjective outcomes, only 2 questionnaires were used consistently enough for meta-analysis

at the posttreatment time point. The 4 studies by Edinger and colleagues (36, 40–42) presented results for the Insomnia Symptom Questionnaire (61), and the pooled results of these studies showed a significant improvement in subjective insomnia severity (12.35 points [CI, 8.28 to 16.43 points]). Five studies reported results for the Pittsburgh Sleep Quality Index (62), of which 4 assessed all items of this tool. Meta-analysis of this outcome revealed a significant improvement at the post-treatment time point (2.31 points [CI, 0.38 to 4.24

Table 3. Characteristics of Randomized, Controlled Trials Assessing the Efficacy of CBT-i

Study, Year (Reference)	Patients Contributing Data to Meta-analysis, n*	Mean Age, y*	Female, %*	Country	Insomnia Definition	CBT-i Components	Comparator	Additional Follow-up Time Points†	Funding Source
Morin et al, 1993 (49)	24	67‡	71	Canada	ICSD§	C, S, R, H‖	Waiting list	–	NIH
Morin et al, 1999 (50)	36	65‡	69	Canada	DSM-IV and ICSD§	C, S, R, H‖	Placebo tablets	3 and 12 mo	NIH
Edinger et al, 2001 (40)	50	56	48	United States	DSM-III-R§	S, R, H	Behavioral placebo	–	NIH
Espie et al, 2001 (43)	139	51	68	United Kingdom	ICSD§	C, S, R, H, X‖	Behavioral placebo	–	Gov
Guilleminault et al, 2002 (45)	68	63	100	United States	NS§	C, S, R, H	Hygiene	6 mo¶	NS
Edinger and Sampson, 2003 (41)	20	51	10	United States	DSM-IV	C, S, R, H	Hygiene	3 mo	VA
Waters et al, 2003 (54)	29	46‡	79	United States	Author-defined§	S, R, H, X	Hygiene	–	Phil
Jacobs et al, 2004 (46)	30	47‡	70	United States	DSM-IV and ICSD	C, S, R, X	Placebo tablets	1 mo	NIH
Sivertsen et al, 2006 (51)	30	61‡	53	Norway	DSM-IV§	C, S, R, H, X‖	Placebo tablets	–	Uni/Gov/Phil
Wu et al, 2006 (55)	36	38	53	China	DSM-IV and ICSD	C, S, R, H	Placebo tablets	3 and 8 mo	Gov
Edinger et al, 2007 (36)	70	55‡	50	United States	DSM-IV§	C, S, R, H	Waiting list	–	NIH
Espie et al, 2007 (44)	201	54	68	United Kingdom	DSM-IV and ICSD Revised	C, S, R, H, X‖	Usual treatment	6 mo	Gov
McCrae et al, 2007 (48)	20	77‡	65	United States	DSM-IV and ICSD-2	S, R, H	Hygiene	–	NIH/USGov
Altena et al, 2008 (37)	25	61	72	The Netherlands	DSM-IV§	C, R, H	Waiting list	–	Gov
Soeffing et al, 2008 (52)	47	64‡	64	United States	ICSD-2§	S, H, X	Behavioral placebo	–	NIH
Edinger et al, 2009 (42)	40	56	13	United States	DSM-IV-TR§ and RDC	C, S, R, H	Hygiene	6 mo	VA
Buysse et al, 2011 (39)	79	72‡	68	United States	DSM-IV-TR and ICSD-2§	S, R, H	Hygiene	–	NIH
Bothelius et al, 2013 (38)	66	51	86	Sweden	RDC	C, S, R, H, X‖	Waiting list	–	Gov
Lovato et al, 2014 (47)	118	64	53	Australia	Author-defined§	C, R, H‖	Waiting list	3 mo	Gov
Taylor et al, 2014 (53)	34	20	59	United States	DSM-5§	C, S, R, H, X	Waiting list	–	Uni

C = cognitive therapy; CBT-i = cognitive behavioral therapy for insomnia; DSM-III-R = *Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised* (56); DSM-IV = *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* (1); DSM-IV-TR = *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision* (57); DSM-5 = *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*; Gov = non-U.S. government source; H = sleep hygiene; ICSD = International Classification of Sleep Disorders (58); ICSD-2 = International Classification of Sleep Disorders, Second Edition (59); NIH = National Institutes of Health, National Institute of Mental Health, or National Institute on Drug Abuse; NS = not stated; Phil = philanthropic foundation; R = sleep restriction; RDC = research diagnostic criteria for insomnia disorder (60); S = stimulus control; Uni = university grant; USGov = U.S. government (federal or state); VA = U.S. Department of Veterans Affairs; X = relaxation.
* Limited to participants included in our analysis rather than entire publication (when different).
† Included in meta-analysis in addition to posttreatment time point.
‡ Additional age restrictions in inclusion criteria.
§ Polysomnographic screening of all patients at baseline.
‖ Group delivery.
¶ Study presented 6-mo follow-up data for non–sleep diary outcomes only and therefore did not contribute data to pooled estimates.

Table 4. Risk-of-Bias Assessments*

Study, Year (Reference)	Sequence Generation	Allocation Concealment	Blinding of Participants and Personnel	Blinding of Outcome Assessment	Incomplete Outcome Data	Selective Outcome Reporting	Other Issues
Morin et al, 1993 (49)	Unclear	Unclear	Unclear	Unclear	Low	Low	Low
Morin et al, 1999 (50)	High	High	High	Unclear	Low	Low	High
Edinger et al, 2001 (40)	Low	Unclear	Low	Unclear	Low	Low	Low
Espie et al, 2001 (43)	Low	High	High	High	High	Low	Low
Guilleminault et al, 2002 (45)	Low	Unclear	Unclear	Low	Low	High	High
Edinger and Sampson, 2003 (41)	Unclear	Unclear	Low	Unclear	Low	Low	Low
Waters et al, 2003 (54)	High	Low	Low	Low	Unclear	Low	Low
Jacobs et al, 2004 (46)	Low	Unclear	High	Unclear	Low	Low	Low
Sivertsen et al, 2006 (51)	Low	Low	Low	Unclear	Low	Low	Low
Wu et al, 2006 (55)	Unclear	Unclear	Unclear	Unclear	Unclear	Low	High
Edinger et al, 2007 (36)	Low	Unclear	Low	Unclear	Low	Low	Low
Espie et al, 2007 (44)	Low	Low	High	High	Low	Low	Low
McCrae et al, 2007 (48)	Unclear	Unclear	Unclear	Unclear	Low	Low	Low
Altena et al, 2008 (37)	Unclear	Unclear	Unclear	Unclear	Low	High	Low
Soeffing et al, 2008 (52)	Unclear	Unclear	Unclear	Unclear	Unclear	Low	Low
Edinger et al, 2009 (42)	Low	Unclear	Low	Unclear	Low	Low	Low
Buysse et al, 2011 (39)	Low	Unclear	Unclear	Unclear	Low	Low	Low
Bothelius et al, 2013 (38)	Low	Low	High	High	Low	Low	Low
Lovato et al, 2014 (47)	Low	Low	Low	Low	Low	Low	Low
Taylor et al, 2014 (53)	Low	Low	High	High	Low	Low	Low

* Domains from the Cochrane Handbook for Systematic Reviews of Interventions (32).

points]). Five studies used the Dysfunctional Beliefs and Attitudes About Sleep Scale (63), but meta-analysis was not possible because of differences in the number of items this tool assessed. Similarly, although the Beck Depression Inventory was used in 5 studies (64) and the Epworth Sleepiness Scale was used in 4 (65), only 3 presented numerical results for each. Other tools used by multiple studies included the Insomnia Severity Index (3 studies) (66), the Profile of Mood States (3 studies) (67), the Short Form-36 (3 studies) (68), self-efficacy scales (4 studies) (69), and components of the State-Trait Anxiety Inventory (4 studies) (70). In addition, several studies used such scales as a component of the initial assessment but not at follow-up time points.

No study reported harms to participants in the CBT-i group, although only 5 explicitly stated that no harms occurred as a result of CBT-i.

Sensitivity Analysis and Publication Bias

None of the sensitivity analyses described earlier revealed consistent differences in effect across diary measures (section 3 of the **Supplement**). Exploratory meta-regression analyses were also performed using sex and the average age of participants, with neither found to be a significant effect modifier of any sleep diary outcome at the posttreatment time point (data not shown). To assess for publication bias, funnel plots were constructed and Egger tests were performed for each outcome variable at the posttreatment time point only, with no statistically significant results found (section 4 of the **Supplement**).

DISCUSSION

We found that CBT-i is an effective treatment for chronic insomnia that produces meaningful improvements in sleep diary outcomes. The marked effects on SOL, WASO, and SE% at the posttreatment time point

seem to have been maintained at both early and late follow-up, and for TST, initially small improvements may augment over time. The sleep diary results are generally consistent with those measured by polysomnography but may be underestimated by actigraphy, for which fewer studies were available for meta-analysis. These improvements in sleep time variables are associated with significant alleviation of symptoms when measured with subjective tools.

We applied narrow inclusion criteria to minimize the heterogeneity of included studies, restricting to multimodal CBT-i compared with inactive comparators in patients with noncomorbid insomnia. This was done because of concern that high levels of heterogeneity may have been present due to differences in the approach to delivering CBT-i, such that allowing wide variation in participants, interventions, and comparators would have precluded meta-analysis. Therefore, although CBT-i, sometimes in an adapted form, is also likely to be effective for comorbid insomnia (71–73), we restricted our analysis to primary chronic insomnia. Although there are 2 well-recognized sets of diagnostic criteria for chronic insomnia, the definitions have increasingly converged with time (31). Meanwhile, a package of interventions incorporating behavioral, cognitive, and educational components has been developed for the condition (74, 75). Although other delivery formats have been shown to be equally effective and have the potential to markedly increase access to CBT-i (76, 77), further research is needed before such treatments can be confirmed to have equivalent long-term reliability and effectiveness (78).

Diary measures of sleep time variables are the most consistently used outcome measures for assessing sleep response in patients with chronic insomnia, partly due to ease of assessment. Many factors, including marked variation in sleeping time (79), limit data collec-

tion with other methods. Therefore, in the management of insomnia, the key outcomes for patients are the subjective sleep outcomes reported as main outcome measures in this analysis. We found significant improvements in 2 questionnaires assessing symptomatic response to treatment, which is consistent with the

known correlation between sleep diary measures and daytime symptoms in persons with insomnia (66, 80, 81). Moreover, some studies found improvement in sleepiness, psychomotor vigilance, mood, anxiety, self-efficacy, beliefs and attitudes about sleep, health status, and daytime functioning.

Figure 2. Meta-analysis of the effect of CBT-i on SOL.

Study, Year (Reference)	Mean Difference (95% CI), *min*
Posttreatment	
Morin et al, 1993 (49)	−21.29 (−43.35 to 0.77)
Espie et al, 2001 (43)	−29.00 (−39.33 to 18.67)
Edinger and Sampson, 2003 (41)	−12.60 (−31.60 to 6.40)
Waters et al, 2003 (54)	2.85 (−19.27 to 24.97)
Jacobs et al, 2004 (46)	−26.00 (−54.13 to 2.13)
Wu et al, 2006 (55)	−22.30 (−56.89 to 12.29)
Edinger et al, 2007 (36)	−10.90 (−25.32 to 3.53)
Espie et al, 2007 (44)	−25.00 (−39.35 to 10.65)
McCrae et al, 2007 (48)	−24.65 (−44.45 to 4.85)
Altena et al, 2008 (37)	−27.70 (−33.03 to 22.37)
Soeffing et al, 2008 (52)	−13.84 (−31.08 to 3.40)
Edinger et al, 2009 (42)	−9.50 (−29.26 to 10.26)
Buysse et al, 2011 (39)	−21.83 (−31.95 to 11.71)
Bothelius et al, 2013 (38)	−5.30 (−34.69 to 24.09)
Lovato et al, 2014 (47)	−9.00 (−18.35 to 0.35)
Taylor et al, 2014 (53)	−29.50 (−55.02 to 3.98)
Knapp–Hartung pooled estimate	−19.03 (−23.93 to 14.12)
Heterogeneity: I^2 = 41.9%; P = 0.040	
Early follow-up	
Edinger and Sampson, 2003 (41)	−15.40 (−34.23 to 3.43)
Jacobs et al, 2004 (46)	−6.80 (−33.32 to 19.72)
Wu et al, 2006 (55)	−44.60 (−78.90 to 10.30)
Lovato et al, 2014 (47)	−2.00 (−11.35 to 7.35)
Knapp–Hartung pooled estimate	−12.18 (−37.52 to 13.15)
Heterogeneity: I^2 = 53.7%; P = 0.091	
Late follow-up	
Wu et al, 2006 (55)	−39.70 (−74.50 to 4.90)
Espie et al, 2007 (44)	−15.50 (−31.10 to 0.10)
Edinger et al, 2009 (42)	0.90 (−19.25 to 21.05)
Knapp–Hartung pooled estimate	−14.24 (−58.36 to 29.88)
Heterogeneity: I^2 = 52.2%; P = 0.123	

−60   −30   0   30

Favors CBT-i   Favors Control

CBT-i = cognitive behavioral therapy for insomnia; SOL = sleep onset latency.

Figure 3. Meta-analysis of the effect of CBT-i on WASO.

Study, Year (Reference)	Mean Difference (95% CI), *min*
Posttreatment	
Morin et al, 1993 (49)	−24.36 (−58.50 to 9.78)
Morin et al, 1999 (50)	−16.78 (−43.38 to 9.82)
Edinger et al, 2001 (40)	−31.70 (−56.68 to 6.72)
Edinger and Sampson, 2003 (41)	−73.60 (−112.78 to 34.42)
Waters et al, 2003 (54)	−11.27 (−33.23 to 10.69)
Edinger et al, 2007 (36)	−23.41 (−46.40 to 0.42)
Espie et al, 2007 (44)	−27.40 (−48.83 to 5.97)
McCrae et al, 2007 (48)	−19.07 (−36.72 to 1.42)
Soeffing et al, 2008 (52)	−24.12 (−60.15 to 11.91)
Edinger et al, 2009 (42)	−9.10 (−35.98 to 17.78)
Buysse et al, 2011 (39)	−20.63 (−36.31 to 4.95)
Bothelius et al, 2013 (38)	−15.00 (−50.05 to 20.05)
Lovato et al, 2014 (47)	−75.60 (102.27 to 48.93)
Taylor et al, 2014 (53)	−20.96 (−35.16 to 6.76)
Knapp–Hartung pooled estimate	−26.00 (−36.52 to 15.48)
Heterogeneity: I^2 = 47.2%; P = 0.026	
Early follow-up	
Morin et al, 1999 (50)	−20.11 (−50.35 to 10.13)
Edinger and Sampson, 2003 (41)	−70.20 (−109.08 to 31.32)
Lovato et al, 2014 (47)	−41.40 (−68.96 to 13.84)
Knapp–Hartung pooled estimate	−41.64 (−101.02 to 17.74)
Heterogeneity: I^2 = 49.9%; P = 0.136	
Late follow-up	
Morin et al, 1999 (50)	−29.33 (−64.31 to 5.65)
Espie et al, 2007 (44)	−26.70 (−52.64 to 0.76)
Edinger et al, 2009 (42)	−3.30 (−29.90 to 23.30)
Knapp–Hartung pooled estimate	−18.38 (−54.45 to 17.68)
Heterogeneity: I^2 = 0.3%; P = 0.37	

CBT-i = cognitive behavioral therapy for insomnia; WASO = wake after sleep onset.

Risk-of-bias assessments found only 1 study to have low risk of bias across all domains. Included studies were generally rigorous with patient follow-up and outcome reporting such that most studies were assessed as low-risk on these domains. Because sleep diary estimates of SOL, WASO, TST, and SE% are among the best-established outcome measures for CBT-i, most included studies reported data for all of these variables. However, allocation concealment and blinding were commonly unreported or not undertaken, probably because of the behavioral nature of the intervention. The risk of bias from incomplete blinding is significant, although complete blinding of all participants and personnel to the nature of a psychological intervention is difficult or impossible. This issue could be exacerbated by the subjective nature of the sleep diary outcomes, although the similar results for polysomnographic outcomes suggest that the improvements were real.

The degree of statistical heterogeneity observed was moderate in some analyses at the posttreatment time point, although sensitivity analyses that restricted by intervention characteristics did not find clear reasons for this heterogeneity. Heterogeneity seemed greater at follow-up time points, with Wu and associates (55) finding a slightly greater effect of treatment, whereas the results of Edinger and colleagues (42) suggested a lesser effect. This may relate to the treatment regimens used, given that Wu and associates delivered

Figure 4. Meta-analysis of the effect of CBT-i on TST.

Study, Year (Reference)	Mean Difference (95% CI), *min*
Posttreatment	
Morin et al, 1993 (49)	2.04 (−47.59 to 51.67)
Morin et al, 1999 (50)	10.84 (−23.95 to 45.63)
Edinger et al, 2001 (40)	−2.00 (−28.87 to 24.87)
Edinger and Sampson, 2003 (41)	33.70 (−4.98 to 72.38)
Jacobs et al, 2004 (46)	19.10 (−25.27 to 63.47)
Sivertsen et al, 2006 (51)	−4.20 (−35.00 to 26.60)
Wu et al, 2006 (55)	56.40 (−18.70 to 94.10)
Edinger et al, 2007 (36)	−9.67 (−32.83 to 13.49)
Espie et al, 2007 (44)	13.20 (−7.62 to 34.02)
McCrae et al, 2007 (48)	−12.32 (−51.07 to 26.43)
Soeffing et al, 2008 (52)	5.37 (−24.49 to 35.23)
Edinger et al, 2009 (42)	13.50 (−31.60 to 58.60)
Buysse et al, 2011 (39)	−6.47 (−28.43 to 15.49)
Bothelius et al, 2013 (38)	10.20 (−17.37 to 37.77)
Lovato et al, 2014 (47)	16.20 (−3.66 to 36.06)
Taylor et al, 2014 (53)	11.78 (−24.09 to 47.65)
Knapp–Hartung pooled estimate	7.61 (−0.51 to 15.74)
Heterogeneity: $I^2 = 3.1\%$; $P = 0.42$	
Early follow-up	
Morin et al, 1999 (50)	−5.23 (−46.39 to 35.93)
Edinger and Sampson, 2003 (41)	47.90 (10.05 to 85.75)
Wu et al, 2006 (55)	62.00 (25.06 to 98.94)
Lovato et al, 2014 (47)	18.60 (−2.45 to 39.65)
Knapp–Hartung pooled estimate	30.31 (−15.14 to 75.76)
Heterogeneity: $I^2 = 60.4\%$; $P = 0.056$	
Late follow-up	
Morin et al, 1999 (50)	65.11 (12.94 to 117.28)
Wu et al, 2006 (55)	63.70 (28.42 to 98.98)
Espie et al, 2007 (44)	25.80 (3.32 to 48.28)
Edinger et al, 2009 (42)	6.50 (−36.21 to 49.21)
Knapp–Hartung pooled estimate	38.05 (−5.34 to 81.43)
Heterogeneity: $I^2 = 51.4\%$; $P = 0.103$	

−30   0   30   60   90

Favors Control   **Favors CBT-i**

CBT-i = cognitive behavioral therapy for insomnia; TST = total sleep time.

Figure 5. Meta-analysis of the effect of CBT-i on SE%.

Study, Year (Reference)		Mean Difference (95% CI), %

Posttreatment

Study	Mean Difference (95% CI), %
Morin et al, 1993 (49)	10.95 (0.12 to 21.78)
Morin et al, 1999 (50)	12.16 (4.45 to 19.87)
Edinger et al, 2001 (40)	6.00 (0.53 to 11.47)
Edinger and Sampson, 2003 (41)	14.90 (8.15 to 21.65)
Jacobs et al, 2004 (46)	10.90 (0.26 to 21.54)
Sivertsen et al, 2006 (51)	5.90 (−1.82 to 13.62)
Wu et al, 2006 (55)	15.20 (6.23 to 24.17)
Edinger et al, 2007 (36)	5.06 (0.03 to 10.09)
Espie et al, 2007 (44)	9.90 (5.22 to 14.58)
McCrae et al, 2007 (48)	10.36 (4.69 to 16.03)
Altena et al, 2008 (37)	13.80 (11.83 to 15.77)
Soeffing et al, 2008 (52)	6.97 (0.47 to 13.47)
Edinger et al, 2009 (42)	4.80 (−2.68 to 12.28)
Buysse et al, 2011 (39)	7.54 (3.31 to 11.77)
Bothelius et al, 2013 (38)	7.40 (1.87 to 12.93)
Lovato et al, 2014 (47)	13.51 (8.79 to 18.23)
Taylor et al, 2014 (53)	13.05 (5.98 to 20.12)
Knapp–Hartung pooled estimate	9.91 (8.09 to 11.73)

Heterogeneity: I^2 = 47.1%; P = 0.017

Early follow-up

Study	Mean Difference (95% CI), %
Morin et al, 1999 (50)	10.39 (1.68 to 19.10)
Edinger and Sampson, 2003 (41)	15.90 (9.40 to 22.40)
Jacobs et al, 2004 (46)	−2.70 (−13.79 to 8.39)
Wu et al, 2006 (55)	24.40 (15.43 to 33.37)
Lovato et al, 2014 (47)	8.29 (3.27 to 13.31)
Knapp–Hartung pooled estimate	11.61 (−0.11 to 23.32)

Heterogeneity: I^2 = 77.3%; P = 0.002

Late follow-up

Study	Mean Difference (95% CI), %
Morin et al, 1999 (50)	18.81 (7.27 to 30.35)
Wu et al, 2006 (55)	17.70 (9.15 to 26.25)
Espie et al, 2007 (44)	9.70 (4.47 to 14.93)
Edinger et al, 2009 (42)	1.30 (−5.62 to 8.22)
Knapp–Hartung pooled estimate	11.10 (−1.67 to 23.87)

Heterogeneity: I^2 = 73.7%; P = 0.010

−10   0   10   20   30

Favors Control   **Favors CBT-i**

CBT-i = cognitive behavioral therapy for insomnia; SE% = sleep efficiency.

twice-weekly sessions for 8 weeks, whereas Edinger and colleagues used 4 sessions. However, methodological differences could also have contributed because several bias domains were assessed as unclear for the study by Wu and associates and there were insufficient studies available at follow-up time points for sensitivity analyses to be performed. Despite the presence of moderate heterogeneity in some analyses, the consistency in estimates of effect was notable given the unavoidable differences in interventions that arise from individual therapists delivering a behavioral intervention. Publication bias is unlikely to have affected our estimates, given that our search strategy included gray literature and we found no statistical evidence of publication bias. Moreover, the labor-intensive nature of trials into behavioral interventions may further limit such bias. The 2 studies assessed as high-risk for selective outcome reporting described changes in sleep time in the text but did not provide figures for the results of at least 3 diary outcomes. However, the text of these studies suggests that the changes in the other sleep diary variables were similar to the results contributing to this review.

At baseline, the mean SOL, WASO, TST, and SE% in the included studies were 57.6 minutes, 76.0 minutes, 344.1 minutes, and 71.8%, respectively. Other studies have found that patients with insomnia differ from healthy control participants in these variables by around 23 minutes, 36 minutes, 95 minutes, and 16%, respectively (80), and that normal polysomnographic SE% is around 80% to 90%, depending on age (82, 83). Therefore, improvements in SOL, WASO, TST, and SE% of 19 minutes, 26 minutes, 7.6 minutes, and 9.9% from these baseline values represent major increases in 3 of these variables. Although CIs were wider because fewer studies were available for meta-analysis, these improvements seemed to be sustained at follow-up time points, which is consistent with patients acquiring the skills required to maintain the gains made earlier in therapy. The modest improvement in TST at the post-treatment time point is consistent with a previous meta-analysis of behavioral therapy versus pharmacotherapy (84), and although the improvements at the late follow-up time point were also not statistically significant, the magnitude of the change seemed to be more marked. This increase is probably a true treatment effect resulting from the sleep restriction intervention, given that initial instructions are to decrease time in bed to better match TST but later increases in time in bed are permitted as SE% improves (Table 1). These results should increase confidence that any treatment-related decrements in TST are likely to be temporary and to affect a minority of patients.

To better place our review in the context of previous ones, we performed a literature search with the same databases, date restrictions, and search terms as for the main analysis described earlier but limited it to systematic reviews and meta-analyses published in English. The results from this search were combined with the results from 2 reviews of reviews of the topic (85, 86). As well as the many descriptive systematic reviews in this area, quantitative meta-analyses have found behavioral interventions for sleep to be efficacious in children (87), CBT-i to be moderately efficacious for anxiety symptoms (88), and CBT-i to be efficacious when delivered in computerized or group-based formats (89, 90). Also, 6 meta-analyses have considered the efficacy of standard CBT-i. Of these, 3 were published in the mid-1990s and so included no more than 1 of the studies contributing to this review (27, 29, 91), and 2 were limited to studies of CBT-i in older adults (26, 92). The remaining meta-analysis by Okajima and coworkers included 14 studies published from 1990 to 2009, of which 9 are included in our review (28). This review differed from our study in that it was not prospectively registered, did not contain a PRISMA statement, and presented results with tables of mean effect sizes. This study also differed by having broader inclusion criteria, allowing inclusion of studies of co-morbid insomnia (93), studies of CBT-i without in-person contact (94, 95), and studies with control groups likely to have significant efficacy (96, 97). Therefore, we believe our review is the most accurate current estimate of the efficacy of CBT-i delivered under standard conditions for patients with chronic insomnia compared with inactive control treatments.

The effect sizes we report are similar in magnitude to those seen in meta-analyses of hypnotics, such as benzodiazepines and "Z drugs" (98, 99), although such studies are often limited by the short duration of treatment and absence of long-term follow-up. However, unlike hypnotics, effects persist after treatment cessation (51). In a direct comparison, CBT-i has been found to be superior to hypnotics for the management of chronic insomnia, with effects sustained over 6 months of follow-up (51). In addition, although hypnotics are an effective treatment for insomnia, limitations include tolerance, adverse effects (100, 101), and rebound insomnia after discontinuation (102). Therefore, because chronic insomnia is a condition in which nearly half of patients remain symptomatic over 10 years (103) and behavioral treatments are likely to be associated with fewer adverse effects (24), CBT-i has several advantages over pharmacotherapy.

Our meta-analysis shows CBT-i to be a highly effective treatment for noncomorbid chronic insomnia, producing clinically meaningful responses. Its efficacy seems to be well-maintained over time and results in significant alleviation of symptoms. This supports recommendations that CBT-i should be used as the initial intervention for chronic insomnia when possible (104).

From Melbourne Sleep Disorders Centre, East Melbourne; Centre for Population Health, The Burnet Institute, and Monash University, Melbourne; Western Health, Footscray; and Monash University, Clayton, Australia.

analysis, as well as Dr. Evan Symons, who assessed 1 article and 1 abstract written in German.

Disclosures: Dr. Rajaratnam reports consultancies for VANDA Pharmaceuticals, Philips Respironics, EdanSafe, organizations employing shift workers, the National Transport Commission, The Australian Workers' Union, and Tontine Group; expert testimony for organizations employing shift workers; grants from VANDA Pharmaceuticals, Philips Respironics, and Cephalon; personal fees from VANDA Pharmaceuticals; and equipment from Compumedics, Optalert, Tyco Healthcare, and Philips Lighting outside the submitted work. He also reports that he was 2014 President and board member of the Australasian Sleep Association and Program Leader of the Co-operative Research Centre for Alertness, Safety and Productivity. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org /authors/icmje/ConflictOfInterestForms.do?msNum=M14 -2841.

Reproducible Research Statement: *Study protocol:* Available at www.crd.york.ac.uk/PROSPERO/display_record.asp?ID= CRD42012002863. *Statistical code and data set:* Available at http: //sleephub.com.au/review-of-cognitive-behavioral -therapy-for-insomnia.

Requests for Single Reprints: James M. Trauer, MBBS, Melbourne Sleep Disorders Centre, Suite 508, Level 5, Victoria Parade, East Melbourne, Victoria 3002, Australia.

Current author addresses and author contributions are available at www.annals.org.

References

1. **American Psychiatric Association.** DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Pr; 1994.

2. **Morin CM, LeBlanc M, Daley M, Gregoire JP, Mérette C.** Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. 2006;7: 123-30. [PMID: 16459140]

3. **Ohayon MM.** Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6:97-111. [PMID: 12531146]

4. **Ohayon MM, Reynolds CF 3rd.** Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD). Sleep Med. 2009;10:952-60. [PMID: 19748312] doi:10.1016/j.sleep.2009 .07.008

5. **Ohayon MM.** Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res. 1997;31:333-46. [PMID: 9306291]

6. **American Psychiatric Association.** Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.

7. **Chang PP, Ford DE, Mead LA, Cooper-Patrick L, Klag MJ.** Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study. Am J Epidemiol. 1997;146:105-14. [PMID: 9230772]

8. **Fernandez ME, Lopez SM, Cazaux A, Cambursano VH, Cortes JR.** [Insomnia: prevalence in Cordoba city hospital]. Rev Fac Cien Med Univ Nac Cordoba. 2012;69:191-6. [PMID: 23751785]

9. **Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A.** Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32:491-7. [PMID: 19413143]

10. **Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Bixler EO.** Insomnia with objective short sleep duration is associated with type 2 diabetes: a population-based study. Diabetes Care. 2009;32: 1980-5. [PMID: 19641160] doi:10.2337/dc09-0284

11. **Smith MT, Haythornthwaite JA.** How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev. 2004;8: 119-32. [PMID: 15033151]

12. **Daley M, Morin CM, LeBlanc M, Grégoire JP, Savard J, Baillargeon L.** Insomnia and its relationship to health-care utilization, work absenteeism, productivity and accidents. Sleep Med. 2009;10:427-38. [PMID: 18753000] doi:10.1016/j.sleep.2008.04.005

13. **Taylor DJ, Lichstein KL, Durrence HH, Reidel BW, Bush AJ.** Epidemiology of insomnia, depression, and anxiety. Sleep. 2005;28: 1457-64. [PMID: 16335332]

14. **Roth T, Jaeger S, Jin R, Kalsekar A, Stang PE, Kessler RC.** Sleep problems, comorbid mental disorders, and role functioning in the national comorbidity survey replication. Biol Psychiatry. 2006;60: 1364-71. [PMID: 16952333]

15. **Breslau N, Roth T, Rosenthal L, Andreski P.** Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39:411-8. [PMID: 8679786]

16. **Roth T, Drake C.** Defining insomnia: the role of quantitative criteria [Editorial]. Sleep. 2006;29:424-5. [PMID: 16676773]

17. **Daley M, Morin CM, LeBlanc M, Grégoire JP, Savard J.** The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep. 2009;32:55-64. [PMID: 19189779]

18. **Kripke DF, Langer RD, Kline LE.** Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open. 2012;2: e000850. [PMID: 22371848] doi:10.1136/bmjopen-2012-000850

19. **International Narcotics Control Board.** Psychotropic Substances: Statistics for 2013. New York: United Nations; 2014.

20. **Charles J, Harrison C, Britt H.** Insomnia. Aust Fam Physician. 2009;38:283. [PMID: 19458795]

21. **Hermes ED, Sernyak M, Rosenheck R.** Use of second-generation antipsychotic agents for sleep and sedation: a provider survey. Sleep. 2013;36:597-600. [PMID: 23565006] doi:10.5665/sleep.2554

22. **Anderson SL, Vande Griend JP.** Quetiapine for insomnia: a review of the literature. Am J Health Syst Pharm. 2014;71:394-402. [PMID: 24534594] doi:10.2146/ajhp130221

23. **Morin CM, Bootzin RR, Buysse DJ, Edinger JD, Espie CA, Lichstein KL.** Psychological and behavioral treatment of insomnia: update of the recent evidence (1998–2004). Sleep. 2006;29:1398-414. [PMID: 17162986]

24. **Vincent N, Lionberg C.** Treatment preference and patient satisfaction in chronic insomnia. Sleep. 2001;24:411-7. [PMID: 11403525]

25. **Harvey AG, Bélanger L, Talbot L, Eidelman P, Beaulieu-Bonneau S, Fortier-Brochu É, et al.** Comparative efficacy of behavior therapy, cognitive therapy, and cognitive behavior therapy for chronic insomnia: a randomized controlled trial. J Consult Clin Psychol. 2014;82: 670-83. [PMID: 24865869] doi:10.1037/a0036606

26. **Montgomery P, Dennis J.** Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Database Syst Rev. 2003:CD003161. [PMID: 12535460]

27. **Morin CM, Culbert JP, Schwartz SM.** Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry. 1994;151:1172-80. [PMID: 8037252]

28. **Okajima I, Komada Y, Inoue Y.** A meta-analysis on the treatment effectiveness of cognitive behavioral therapy for primary insomnia. Sleep Biol Rhythms. 2011;9:24-34.

29. **Murtagh DR, Greenwood KM.** Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol. 1995;63:79-89. [PMID: 7896994]

30. **Trauer J, Cunnington D, Rajaratnam S, Qian M, Doyle J.** Cognitive behavioural therapy for insomnia, a systematic review and meta-analysis. PROSPERO International Prospective Register of Systematic Reviews. 2012.

31. **Morin CM, Benca R.** Chronic insomnia. Lancet. 2012;379:1129-41. [PMID: 22265700] doi:10.1016/S0140-6736(11)60750-2

32. Cochrane Collaboration. The Cochrane Collaboration's Tool for Assessing Risk of Bias. 2011. Accessed at http://ohg.cochrane.org /sites/ohg.cochrane.org/files/uploads/Risk of bias assessment tool .pdf on 20 May 2015.

33. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. [PMID: 12958120]

34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34. [PMID: 9310563]

35. Fernando A 3rd, Arroll B, Falloon K. A double-blind randomised controlled study of a brief intervention of bedtime restriction for adult patients with primary insomnia. J Prim Health Care. 2013;5:5-10. [PMID: 23457689]

36. Edinger JD, Wohlgemuth WK, Radtke RA, Coffman CJ, Carney CE. Dose-response effects of cognitive-behavioral insomnia therapy: a randomized clinical trial. Sleep. 2007;30:203-12. [PMID: 17326546]

37. Altena E, Van Der Werf YD, Strijers RL, Van Someren EJ. Sleep loss affects vigilance: effects of chronic insomnia and sleep therapy. J Sleep Res. 2008;17:335-43. [PMID: 18844819] doi:10.1111/j.1365 -2869.2008.00671.x

38. Bothelius K, Kyhle K, Espie CA, Broman JE. Manual-guided cognitive-behavioural therapy for insomnia delivered by ordinary primary care personnel in general medical practice: a randomized controlled effectiveness trial. J Sleep Res. 2013;22:688-96. [PMID: 23859625] doi:10.1111/jsr.12067

39. Buysse DJ, Germain A, Moul DE, Franzen PL, Brar LK, Fletcher ME, et al. Efficacy of brief behavioral treatment for chronic insomnia in older adults. Arch Intern Med. 2011;171:887-95. [PMID: 21263078] doi:10.1001/archinternmed.2010.535

40. Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA. 2001;285:1856-64. [PMID: 11308399]

41. Edinger JD, Sampson WS. A primary care "friendly" cognitive behavioral insomnia therapy. Sleep. 2003;26:177-82. [PMID: 12683477]

42. Edinger JD, Olsen MK, Stechuchak KM, Means MK, Lineberger MD, Kirby A, et al. Cognitive behavioral therapy for patients with primary insomnia or insomnia associated predominantly with mixed psychiatric disorders: a randomized clinical trial. Sleep. 2009;32:499-510. [PMID: 19413144]

43. Espie CA, Inglis SJ, Tessier S, Harvey L. The clinical effectiveness of cognitive behaviour therapy for chronic insomnia: implementation and evaluation of a sleep clinic in general medical practice. Behav Res Ther. 2001;39:45-60. [PMID: 11125723]

44. Espie CA, MacMahon KM, Kelly HL, Broomfield NM, Douglas NJ, Engleman HM, et al. Randomized clinical effectiveness trial of nurse-administered small-group cognitive behavior therapy for persistent insomnia in general practice. Sleep. 2007;30:574-84. [PMID: 17552372]

45. Guilleminault C, Palombini L, Poyares D, Chowdhuri S. Chronic insomnia, premenopausal women and sleep disordered breathing: part 2. Comparison of nondrug treatment trials in normal breathing and UARS post-menopausal women complaining of chronic insomnia. J Psychosom Res. 2002;53:617-23. [PMID: 12127180]

46. Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med. 2004;164: 1888-96. [PMID: 15451764]

47. Lovato N, Lack L, Wright H, Kennaway DJ. Evaluation of a brief treatment program of cognitive behavior therapy for insomnia in older adults. Sleep. 2014;37:117-26. [PMID: 24470701] doi:10.5665 /sleep.3320

48. McCrae CS, McGovern R, Lukefahr R, Stripling AM. Research Evaluating Brief Behavioral Sleep Treatments for Rural Elderly (RESTORE): a preliminary examination of effectiveness. Am J Geriatr Psychiatry. 2007;15:979-82. [PMID: 17974868]

49. Morin CM, Kowatch RA, Barry T, Walton E. Cognitive-behavior therapy for late-life insomnia. J Consult Clin Psychol. 1993;61:137-46. [PMID: 8450099]

50. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;281:991-9. [PMID: 10086433]

51. Sivertsen B, Omvik S, Pallesen S, Bjorvatn B, Havik OE, Kvale G, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA. 2006;295:2851-8. [PMID: 16804151]

52. Soeffing JP, Lichstein KL, Nau SD, McCrae CS, Wilson NM, Aguillard RN, et al. Psychological treatment of insomnia in hypnotic-dependant older adults. Sleep Med. 2008;9:165-71. [PMID: 17644419]

53. Taylor DJ, Zimmerman MR, Gardner CE, Williams JM, Grieser EA, Tatum JI, et al. A pilot randomized controlled trial of the effects of cognitive-behavioral therapy for insomnia on sleep and daytime functioning in college students. Behav Ther. 2014;45:376-89. [PMID: 24680232] doi:10.1016/j.beth.2013.12.010

54. Waters WF, Hurry MJ, Binks PG, Carney CE, Lajos LE, Fuller KH, et al. Behavioral and hypnotic treatments for insomnia subtypes. Behav Sleep Med. 2003;1:81-101. [PMID: 15600131]

55. Wu R, Bao J, Zhang C, Deng J, Long C. Comparison of sleep condition and sleep-related psychological activity after cognitive-behavior and pharmacological therapy for chronic insomnia. Psychother Psychosom. 2006;75:220-8. [PMID: 16785771]

56. Structured clinical interview for DSM-III-R (SCID). Washington, DC: American Psychiatric Pr; 1990.

57. Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR). 4th ed. Washington, DC: American Psychiatric Assoc; 1997.

58. International Classification of Sleep Disorders (ICSD): Diagnostic and Coding Manual. Rochester, MN: American Sleep Disorders Assoc; 1990.

59. The International Classification of Sleep Disorders. 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005.

60. Edinger JD, Bonnet MH, Bootzin RR, Doghramji K, Dorsey CM, Espie CA, et al; American Academy of Sleep Medicine Work Group. Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine Work Group. Sleep. 2004;27: 1567-96. [PMID: 15683149]

61. Spielman AJ, Saskin P, Thorpy MJ. Treatment of chronic insomnia by restriction of time in bed. Sleep. 1987;10:45-56. [PMID: 3563247]

62. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193-213. [PMID: 2748771]

63. Morin CM, Stone J, Trinkle D, Mercer J, Remsberg S. Dysfunctional beliefs and attitudes about sleep among older adults with and without insomnia complaints. Psychol Aging. 1993;8:463-7. [PMID: 8216967]

64. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-71. [PMID: 13688369]

65. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540-5. [PMID: 1798888]

66. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297-307. [PMID: 11438246]

67. McNair D, Lorr M, Droppleman L. Profile of Mood States. San Diego: Educational and Industrial Testing Service; 1971.

68. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-83. [PMID: 1593914]

69. Lacks P. Behavioral Treatment for Persistent Insomnia. New York: Pergamon Pr; 1987.

70. Spielberger C, Gorsuch R, Lushene R. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Pr; 1970.

71. Smith MT, Huang MI, Manber R. Cognitive behavior therapy for chronic insomnia occurring within the context of medical and psychiatric disorders. Clin Psychol Rev. 2005;25:559-92. [PMID: 15970367]

72. Taylor DJ, Pruiksma KE. Cognitive and behavioural therapy for insomnia (CBT-I) in psychiatric populations: a systematic review. Int Rev Psychiatry. 2014;26:205-13. [PMID: 24892895] doi:10.3109/09540261.2014.902808

73. Ashworth DK, Sletten TL, Junge M, Simpson K, Clarke D, Cunnington D, et al. A randomized controlled trial of cognitive behavioral therapy for insomnia: an effective treatment for comorbid insomnia and depression. J Couns Psychol. 2015;62:115-23. [PMID: 25867693] doi:10.1037/cou0000059

74. Morin CM, Espie CA. Insomnia: A Clinical Guide to Assessment and Treatment. New York: Kluwer Academic/Plenum; 2003.

75. Edinger JD, Carney CE. Overcoming Insomnia: A Cognitive-Behavioral Therapy Approach. Therapist Guide. New York: Oxford Univ Pr; 2008.

76. Arnedt JT, Cuddihy L, Swanson LM, Pickett S, Aikens J, Chervin RD. Randomized controlled trial of telephone-delivered cognitive behavioral therapy for chronic insomnia. Sleep. 2013;36:353-62. [PMID: 23450712] doi:10.5665/sleep.2448

77. Espie CA, Kyle SD, Williams C, Ong JC, Douglas NJ, Hames P, et al. A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep. 2012;35:769-81. [PMID: 22654196] doi:10.5665/sleep.1872

78. Cunnington D, Junge MF, Fernando AT. Insomnia: prevalence, consequences and effective treatment. Med J Aust. 2013;199:S36-40. [PMID: 24138364]

79. Vallières A, Ivers H, Bastien CH, Beaulieu-Bonneau S, Morin CM. Variability and predictability in sleep patterns of chronic insomniacs. J Sleep Res. 2005;14:447-53. [PMID: 16364146]

80. Buysse DJ, Thompson W, Scott J, Franzen PL, Germain A, Hall M, et al. Daytime symptoms in primary insomnia: a prospective analysis using ecological momentary assessment. Sleep Med. 2007;8:198-208. [PMID: 17368098]

81. Gu NY, Botteman MF, Ji X, Bell CF, Carter JA, van Hout B. Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities. Health Qual Life Outcomes. 2011;9:119. [PMID: 22208861] doi:10.1186/1477-7525-9-119

82. Bonnet MH, Arand DL. EEG arousal norms by age. J Clin Sleep Med. 2007;3:271-4. [PMID: 17561594]

83. Walsleben JA, Kapur VK, Newman AB, Shahar E, Bootzin RR, Rosenberg CE, et al. Sleep and reported daytime sleepiness in normal subjects: the Sleep Heart Health Study. Sleep. 2004;27:293-8. [PMID: 15124725]

84. Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159:5-11. [PMID: 11772681]

85. De Niet GJ, Tiemens BG, Kloos MW, Hutschemaekers GJ. Review of systematic reviews about the efficacy of non-pharmacological interventions to improve sleep quality in insomnia. Int J Evid Based Healthc. 2009;7:233-42. [PMID: 21631864] doi:10.1111/j.1744-1609.2009.00142.x

86. Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit Ther Res. 2012;36:427-440. [PMID: 23459093]

87. Meltzer LJ, Mindell JA. Systematic review and meta-analysis of behavioral interventions for pediatric insomnia. J Pediatr Psychol. 2014;39:932-48. [PMID: 24947271] doi:10.1093/jpepsy/jsu041

88. Belleville G, Cousineau H, Levrier K, St-Pierre-Delorme MÈ. Meta-analytic review of the impact of cognitive-behavior therapy for insomnia on concomitant anxiety. Clin Psychol Rev. 2011;31:638-52. [PMID: 21482322] doi:10.1016/j.cpr.2011.02.004

89. Cheng SK, Dizon J. Computerised cognitive behavioural therapy for insomnia: a systematic review and meta-analysis. Psychother Psychosom. 2012;81:206-16. [PMID: 22585048] doi:10.1159/000335379

90. Koffel EA, Koffel JB, Gehrman PR. A meta-analysis of group cognitive behavioral therapy for insomnia. Sleep Med Rev. 2015;19:6-16. [PMID: 24931811] doi:10.1016/j.smrv.2014.05.001

91. Pallesen S, Nordhus IH, Kvale G. Nonpharmacological interventions for insomnia in older adults: a meta-analysis of treatment efficacy. Psychotherapy (Chic). 1998;35:472-82.

92. Irwin MR, Cole JC, Nicassio PM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol. 2006;25:3-14. [PMID: 16448292]

93. Rybarczyk B, Lopez M, Benson R, Alsten C, Stepanski E. Efficacy of two behavioral treatment programs for comorbid geriatric insomnia. Psychol Aging. 2002;17:288-98. [PMID: 12061413]

94. Mimeault V, Morin CM. Self-help treatment for insomnia: bibliotherapy with and without professional guidance. J Consult Clin Psychol. 1999;67:511-9. [PMID: 10450621]

95. Ström L, Pettersson R, Andersson G. Internet-based treatment for insomnia: a controlled evaluation. J Consult Clin Psychol. 2004;72:113-20. [PMID: 14756620]

96. Perlis ML, Smith MT, Orff H, Enright T, Nowakowski S, Jungquist C, et al. The effects of modafinil and cognitive behavior therapy on sleep continuity in patients with primary insomnia. Sleep. 2004;27:715-25. [PMID: 15283007]

97. Jansson M, Linton SJ. Cognitive-behavioral group therapy as an early intervention for insomnia: a randomized controlled trial. J Occup Rehabil. 2005;15:177-90. [PMID: 15844675]

98. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF 3rd, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA. 1997;278:2170-7. [PMID: 9417012]

99. Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012;345:e8343. [PMID: 23248080] doi:10.1136/bmj.e8343

100. Hoque R, Chesson AL Jr. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med. 2009;5:471-6. [PMID: 19961034]

101. Zammit G. Comparative tolerability of newer agents for insomnia. Drug Saf. 2009;32:735-48. [PMID: 19670914] doi:10.2165/11312920-000000000-00000

102. Kales A, Manfredi RL, Vgontzas AN, Bixler EO, Vela-Bueno A, Fee EC. Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin Pharmacol Ther. 1991;49:468-76. [PMID: 2015735]

103. Janson C, Lindberg E, Gislason T, Elmasry A, Boman G. Insomnia in men-a 10-year prospective population based study. Sleep. 2001;24:425-30. [PMID: 11403527]

104. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487-504. [PMID: 18853708]

Current Author Addresses: Drs. Trauer, Qian, and Cunnington: Melbourne Sleep Disorders Centre, Suite 508, Level 5, Victoria Parade, East Melbourne, Victoria 3002, Australia.
Dr. Doyle: The Burnet Institute, 85 Commercial Road, Melbourne, Victoria 3004, Australia.
Dr. Rajaratnam: School of Psychological Sciences, 18 Innovation Walk, Monash University, Wellington Road, Clayton, Victoria 3800, Australia.

Author Contributions: Conception and design: J.M. Trauer, J.S. Doyle, S.M.W. Rajaratnam, D. Cunnington.
Analysis and interpretation of the data: J.M. Trauer, M.Y. Qian, J.S. Doyle, S.M.W. Rajaratnam, D. Cunnington.
Drafting of the article: J.M. Trauer, M.Y. Qian.
Critical revision of the article for important intellectual content: J.M. Trauer, J.S. Doyle, D. Cunnington.
Final approval of the article: J.M. Trauer, M.Y. Qian, J.S. Doyle, S.M.W. Rajaratnam, D. Cunnington.
Statistical expertise: J.M. Trauer, J.S. Doyle.
Administrative, technical, or logistic support: D. Cunnington.
Collection and assembly of data: J.M. Trauer, M.Y. Qian, D. Cunnington.

Appendix Table. Secondary Outcomes

Outcome	Effect Size (95% CI)	Studies, *n*
Polysomnography		
SOL, *min*	No estimate*	2
WASO, *min*	−29.14 (−52.61 to −5.67)	2
TST, *min*	10.03 (−32.48 to 52.54)	5
SE%, %	6.46 (2.83 to 10.08)	5
Actigraphy		
SOL, *min*	−1.16 (−8.96 to 6.63)	3
WASO, *min*	−9.53 (−23.45 to 4.38)	4
TST, *min*	−38.13 (−103.79 to 27.54)	3
SE%, %	1.53 (−0.48 to 3.54)	4
Questionnaire		
Insomnia Severity Index	−12.35 (−16.43 to −8.28)	4
Pittsburgh Sleep Quality Index	−2.31 (−4.24 to −0.38)	4

SE% = sleep efficiency; SOL = sleep onset latency; TST = total sleep time; WASO = wake after sleep onset.
* Heterogeneity of 2 studies reporting this outcome was too great to report pooled estimate.